

# **Country Funding Update**

#### 53<sup>rd</sup> Board Meeting

GF/B53/04

7 – 9 May 2025, Geneva, Switzerland

For Information



#### **Executive Summary**

- TRP funding request review for GC7 is now complete, with a 3% iteration rate of funding requests for this cycle.
- 241 GC7 grants have been Board Approved, including 95% of allocation funding and 94% of matching funds. Approximately 21 new grants remain for GAC review and recommendation and Board approval by the end of 2025.
- Catalytic multicountry funds have a lower percentage Board-approved to date (72%) due to later applicant submissions in the funding cycle.
- US\$1 billion of GC7 UQD has been funded, primarily through savings and efficiencies in grant-making. US\$5.7 billion remains unfunded.

# **Funding Request Registrations by TRP Window**


183 out of 188 Funding Requests reviewed by TRP in Windows 1 to 7 were recommended for grant-making on first review, representing a 3% iteration rate.

HIV/AIDSTuberculosisTB/HIVMalaria

Multi-Component
Standalone RSSH

Multicountry


Iteration





# **Allocation Amount by TRP Window**

In Windows 1 to 7, US\$13.1 billion was recommended for grant-making.





Note: Allocation amount is based on recommended allocation (if approved), requested allocation (if submitted), current program split (if agreed) or communicated allocation.

HIV/AIDSTuberculosis


■ TB/HIV ■ Malaria


Multi-Component
Standalone RSSH

MulticountryIteration

# **GC7 GAC Registrations**

241 grants for GC7 have been Board-approved and have started implementation. The Secretariat expects approximately 21 new grants to be submitted for GAC review and recommendation and Board approval in 2025.






Source: GOS as of 07 April 2025

# Allocation funding: as of April 2025


US\$13.128 billion is available for country allocations, of which US\$12.45 billion (95%) is now integrated into Board-approved grants.





# **Matching Funds: as of April 2025**


Of US\$274.7 million designated for Matching Funds, US\$259.1 million (94%) is now integrated into Board-approved grants.





#### **Multicountry Funds: as of April 2025**


Of the US\$110 million designated for catalytic Multicountry Funds, US\$79.5 million (72%) is now integrated into Board-approved grants. The first HIV catalytic multicountry grant has been approved and remaining multicountry grants are now in negotiation.





#### **GC7 Unfunded Quality Demand**

To date the TRP has recommended **US\$6.8 billion** as UQD, of which more than US\$1 billion has been funded by savings and efficiencies in grant-making. US\$5.7 billion remains on the UQD Register.



#### **Unfunded Quality Demand Comparison GC5 to GC7**

The Remaining UQD in GC7 is higher than it was in GC6 or GC5 at the corresponding period in the allocation cycle and remains relatively evenly split between the three disease components and RSSH.

